References
- Cripe L. D. Adult acute leukemia. Curr. Probl. in Cancer 1997; 21: 1–64
- Goldstein J. L., Brown M. S. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430
- Dimitroulakos J., Nohynek D., Backway K. L., Hedley D. W., Yeger H., Freedman M. H., Minden M. D., Penn L. Z. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 1999; 93: 1308–1318
- Corsini A., Maggi F. M., Catapano A. L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacological Research 1995; 31: 9–27
- Dimitroulakos J., Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells. Nature Med. 1996; 2: 326–333
- Dimitroulakos J., Thai S., Wasfy G. H., Hedley D. W., Minden M. D., Penn L. Z. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk. Lymph. 2000
- Thibault A., Samid D., Tompkins A. C., Figg W. D., Cooper M. R., Hohl R. J., Trepel J., Liang B., Patronas N., Venzon D. J., Reed E., Myers C. E. Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 1996; 2: 483–491
- Newman A., Clutterbuck R. D., Powles R. L., Catovsky D., Millar J. L. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin, and prevastatin on leukaemic and normal bone marrow progenitors. Leuk. Lymph. 1997; 24: 533–537